Package 75834-159-05

{"route": ["ORAL"], "spl_id": "ebbb0dad-ab4d-4d6c-aebb-d65e2dd08c28", "openfda": {"upc": ["0375834320052", "0375834320014"], "unii": ["V3888OEY5R"], "rxcui": ["897640", "897649", "897659"], "spl_set_id": ["e36e485f-fbed-4e30-9a63-984931f2e54e"], "manufacturer_name": ["Nivagen Pharmaceuticals, Inc."], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "100 TABLET in 1 BOTTLE (75834-159-01)", "package_ndc": "75834-159-01", "marketing_start_date": "20190515"}, {"sample": false, "description": "500 TABLET in 1 BOTTLE (75834-159-05)", "package_ndc": "75834-159-05", "marketing_start_date": "20190515"}], "brand_name": "VERAPAMIL HYDROCHLORIDE", "product_id": "75834-159_ebbb0dad-ab4d-4d6c-aebb-d65e2dd08c28", "dosage_form": "TABLET", "pharm_class": ["Calcium Channel Antagonists [MoA]", "Calcium Channel Blocker [EPC]", "Cytochrome P450 3A Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]"], "product_ndc": "75834-159", "generic_name": "VERAPAMIL HYDROCHLORIDE", "labeler_name": "Nivagen Pharmaceuticals, Inc.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "VERAPAMIL HYDROCHLORIDE", "active_ingredients": [{"name": "VERAPAMIL HYDROCHLORIDE", "strength": "240 mg/1"}], "application_number": "ANDA206173", "marketing_category": "ANDA", "marketing_start_date": "20190515", "listing_expiration_date": "20261231"}